Sort
78,016 grants matching “breast cancer”
Shared Resources Core-1: Integrated Clinical, Tissue, and Biomarker Data Base Core (ICTBD Core)
$458,276Jaydutt V Vadgama · Charles R. Drew University Of Med & Sci · U54 · FY2019 · CA
In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
$458,203Zelig Eshhar · Tel-Aviv Sourasky Medical Center · R01 · FY2013 · EB
An innate immune checkpoint in cancer immunotherapy
$458,186Carla Rothlin · Yale University · R01 · FY2021 · CA
Molecular and Genetic Determinants of Invasion in HNSCC
$458,170Cun-Yu Wang · University Of California Los Angeles · R01 · FY2012 · DE
Molecular and Genetic Determinants of Invasion in HNSCC
$458,170Cun-Yu Wang · University Of California Los Angeles · R01 · FY2014 · DE
01 Project 1: Cancer risks for mutations in breast cancer predisposition genes
$458,126Fergus Joseph Couch · Mayo Clinic Rochester · P50 · FY2019 · CA
Cancer and Leukemia Group B
$458,112Dana-Farber Cancer Institute · U10 · FY2003 · CA
Early Determinants of Mammographic Density
$458,093Mary Beth Terry · Columbia University Health Sciences · R01 · FY2007 · CA
Molecular Targets for Cancer Detection and Treatment
$458,089William George Nelson · Johns Hopkins University · T32 · FY2009 · CA
SEQUENCING TUMOR SUPPRESSOR LOCI
$458,084Cold Spring Harbor Laboratory · R01 · FY2002 · CA
Growth Hormones and Breast Cancer Risk
$458,063Shelley S Tworoger · Brigham And Women'S Hospital · R01 · FY2010 · CA
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolism
$458,041Rakesh K. Jain · Massachusetts General Hospital · R01 · FY2022 · CA
Translational Control in IPF
$458,034Peter B Bitterman · University Of Minnesota · R01 · FY2008 · HL
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
$457,974Anna Tate Riegel · Georgetown University · R01 · FY2017 · CA
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
$457,974Anna Tate Riegel · Georgetown University · R01 · FY2020 · CA
(PQ6) Molecular Mechanisms Driving Benign to Malignant Transitions in Breast Cancer
$457,974Anna Tate Riegel · Georgetown University · R01 · FY2018 · CA
HRT USE AND RISK OF LOBULAR AND DUCTAL BREAST CANCER
$457,972Fred Hutchinson Cancer Research Center · R01 · FY2004 · CA
01 - Cancer Biology & Immunology
$457,961Robert S Welner · University Of Alabama At Birmingham · P30 · FY2025 · CA
Shared Resource Management
$457,959Erwin G Van Meir · University Of Alabama At Birmingham · P30 · FY2025 · CA
Community Outreach and Engagement
$457,959Timiya S Nolan · University Of Alabama At Birmingham · P30 · FY2025 · CA
04 - Cancer Control and Population Sciences
$457,959Laura Q Rogers · University Of Alabama At Birmingham · P30 · FY2025 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence
$457,959Katherine Elena Varley · University Of Utah · R01 · FY2019 · CA
02 - Experimental Therapeutics
$457,959Suzanne Elizabeth Lapi · University Of Alabama At Birmingham · P30 · FY2025 · CA
Developmental Funds
$457,959Michael J Bertram · University Of Alabama At Birmingham · P30 · FY2025 · CA
Risk Assessment in Community Practice: Developing Better Models
$457,911Karla M Kerlikowske · Kaiser Foundation Health Plan Of Washington · P01 · FY2014 · CA